These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18787357)

  • 1. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany.
    Gattermann N; Hofmann WK; Meessen A; Schmitz S; Tsamaloukas A; Vollmer T; Wedding U; Plesnila-Frank C; Schramm W; Berger K
    Onkologie; 2008 Sep; 31(8-9):477-84. PubMed ID: 18787357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective.
    Kühne F; Mittendorf T; Germing U; Tesch H; Weinberg R; Grabenhorst U; Mohr A; Lipp R; von der Schulenburg JM
    Ann Hematol; 2010 Dec; 89(12):1239-47. PubMed ID: 20574731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing patients with low-risk MDS.
    Sekeres M; Cosgrove D; Falco A
    Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
    Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
    Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive care including growth factors in myelodysplastic syndromes.
    Gardin C; Fenaux P
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E3. PubMed ID: 16027101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis.
    Gattermann N; Kündgen A; Kellermann L; Zeffel M; Paessens B; Germing U
    Onkologie; 2012; 35(6):350-6. PubMed ID: 22722455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS).
    Fenaux P
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S11-5. PubMed ID: 16085012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myelodysplastic syndromes].
    Paladini G; Pecorari P; De Sabbata G; Sammartini C
    Recenti Prog Med; 2004 Feb; 95(2):108-19. PubMed ID: 15072397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes in the adolescent.
    Winter SS; Mathew P; Vaughan RL; Foucar K
    Adolesc Med; 1999 Oct; 10(3):401-6, x. PubMed ID: 10611937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.
    Heptinstall K;
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):13-8; discussion 19. PubMed ID: 18434977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications.
    Gupta P; LeRoy SC; Luikart SD; Bateman A; Morrison VA
    Leuk Res; 1999 Oct; 23(10):953-9. PubMed ID: 10573142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myelodysplastic syndromes.
    Nguyen PL
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):675-91. PubMed ID: 19577164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006.
    De Roos AJ; Deeg HJ; Onstad L; Kopecky KJ; Bowles EJ; Yong M; Fryzek J; Davis S
    Am J Hematol; 2010 Oct; 85(10):765-70. PubMed ID: 20815079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.
    Goldberg SL; Chen E; Corral M; Guo A; Mody-Patel N; Pecora AL; Laouri M
    J Clin Oncol; 2010 Jun; 28(17):2847-52. PubMed ID: 20421543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusions at home in patients with myelodysplastic syndromes.
    Niscola P; Tendas A; Giovannini M; Cupelli L; Trawinska MM; Palombi M; Scaramucci L; Brunetti GA; Perrotti A; Neri B; Efficace F; Cartoni C; de Fabritiis P; Mandelli F
    Leuk Res; 2012 Jun; 36(6):684-8. PubMed ID: 22336393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.